To develop a genetic approach for the treatment of pain, we introduced a recombinant adeno-associated viral (rAAV) vector containing the cDNA for the -opioid receptor (OR) into primary afferent neurons in dorsal root ganglia (DRGs) of rats, which resulted in a long-lasting (>6 months) increase in OR expression in DRG neurons. The increase greatly potentiated the antinociceptive effects of morphine in rAAV-OR-infected rats with and without inflammation. Perforated patch recordings indicated that the efficacy and potency of opioid inhibition of voltage-dependent Ca 2؉ channels were enhanced in infected neurons, which may underlie the increase in opiate efficacy. These data suggest that transfer of opioid receptor genes into DRG cells with rAAV vectors may offer a new therapeutic strategy for pain management. C hronic pain often causes anguish in patients who suffer from long-term illnesses (e.g., cancer, arthritis, heart disease) or injuries to the nervous system (e.g., spinal cord injury, loss of a limb; ref. 1). Because of their prominent analgesic potency, opiates have remained the drugs of choice for treating many patients with severe pain. The use of opiates, however, sometimes falls short of therapeutic goals because high doses of opiates frequently produce side effects, including respiratory depression, constipation, and tolerance (2-5). New opioid ligands and intrathecal administration have been used to improve opioid efficacy and curtail side effects. More recently, genetic approaches have been attempted (6, 7). Opioid precursor genes, such as those for enkephalin or ␤-endorphin, were transferred to primary afferent neurons in dorsal root ganglia (DRGs) or the meninges surrounding the spinal cord (7-11). These result in an enhanced production of opioid peptides and a reduction of capsaicin or carrageenan-induced hyperalgesia. However, the antinociceptive effects usually lasted for a short period (1-8 weeks), and some viral vectors produced cytotoxicity. To circumvent these drawbacks, we took a different genetic transfer approach. Recombinant adeno-associated viral (rAAV) vectors, which provide efficient and stable expression in central (12, 13) and peripheral neurons (14, 15), were chosen for gene delivery. A rAAV vector containing the -opioid receptor (OR) gene was introduced into DRGs. Here we show that the OR expression under the control of a neuron-specific enolase (NSE) promoter results in long-term (Ͼ6 months) enhancement of OR transgene expression in DRG neurons. The enhancement markedly potentiates morphine antinociceptive responses to thermal stimuli under normal and inflamed conditions. The increase in opioid efficacy is in part the result of enhanced blockade of high-threshold voltage-dependent Ca 2ϩ channels.
To develop a genetic approach for the treatment of pain, we introduced a recombinant adeno-associated viral (rAAV) vector containing the cDNA for the -opioid receptor (OR) into primary afferent neurons in dorsal root ganglia (DRGs) of rats, which resulted in a long-lasting (>6 months) increase in OR expression in DRG neurons. The increase greatly potentiated the antinociceptive effects of morphine in rAAV-OR-infected rats with and without inflammation. Perforated patch recordings indicated that the efficacy and potency of opioid inhibition of voltage-dependent Ca 2؉ channels were enhanced in infected neurons, which may underlie the increase in opiate efficacy. These data suggest that transfer of opioid receptor genes into DRG cells with rAAV vectors may offer a new therapeutic strategy for pain management. C hronic pain often causes anguish in patients who suffer from long-term illnesses (e.g., cancer, arthritis, heart disease) or injuries to the nervous system (e.g., spinal cord injury, loss of a limb; ref. 1). Because of their prominent analgesic potency, opiates have remained the drugs of choice for treating many patients with severe pain. The use of opiates, however, sometimes falls short of therapeutic goals because high doses of opiates frequently produce side effects, including respiratory depression, constipation, and tolerance (2) (3) (4) (5) . New opioid ligands and intrathecal administration have been used to improve opioid efficacy and curtail side effects. More recently, genetic approaches have been attempted (6, 7) . Opioid precursor genes, such as those for enkephalin or ␤-endorphin, were transferred to primary afferent neurons in dorsal root ganglia (DRGs) or the meninges surrounding the spinal cord (7) (8) (9) (10) (11) . These result in an enhanced production of opioid peptides and a reduction of capsaicin or carrageenan-induced hyperalgesia. However, the antinociceptive effects usually lasted for a short period (1-8 weeks) , and some viral vectors produced cytotoxicity. To circumvent these drawbacks, we took a different genetic transfer approach. Recombinant adeno-associated viral (rAAV) vectors, which provide efficient and stable expression in central (12, 13) and peripheral neurons (14, 15) , were chosen for gene delivery. A rAAV vector containing the -opioid receptor (OR) gene was introduced into DRGs. Here we show that the OR expression under the control of a neuron-specific enolase (NSE) promoter results in long-term (Ͼ6 months) enhancement of OR transgene expression in DRG neurons. The enhancement markedly potentiates morphine antinociceptive responses to thermal stimuli under normal and inflamed conditions. The increase in opioid efficacy is in part the result of enhanced blockade of high-threshold voltage-dependent Ca 2ϩ channels.
Materials and Methods
All experiments were approved by the Institutional Animal Care and Use Committee at the University of Texas Medical Branch.
Preparation of rAAV Plasmid Constructs and Viral Stocks. The plasmid pTR-NSE and pTR-NSE-enhanced GFP (EGFP) were prepared as described (16) . The MOR-1 gene-containing plasmid pCMV-OR (a gift from H. Akil, Univ. of Michigan, Ann Arbor; ref. 17 ) was used as the template for PCR amplification to insert a SalI site to the 5Ј end and a 6ϫHis peptide sequence followed by a HindIII site to the 3Ј end of the OR gene. The PCR products were digested by SalI and HindIII. The resulting fragment was ligated into the SalI͞HindIII sites of pTR-NSE to generate pTR-NSE-OR. rAAV viral particles were produced in an adenovirus-free system by cotransfecting HEK 293 cells with a rAAV vector plasmid (i.e., pTR-NSE-OR or pTR-NSE-EGFP), plasmid pXX2, and pXX6 (16, 18) . Cells were collected and lysed, and cellular debris was eliminated by centrifugation to gain crude viral solution. The viral solution was fractionated through a Heparin Agarose type I column (Sigma) to yield a purified viral stock.
Infection of DRG Neurons with rAAVs. Primary neuronal cultures were prepared from DRGs of 14-day Sprague-Dawley rats as described (19) . Cells were plated onto coverslips and grown in MEM (GIBCO͞BRL) with 10% FBS. To infect cultured DRG neurons, a serum-free medium containing 1 l of viral solution was added to DRG cultures 24-48 h after plating. Ninety minutes later, additional serum (20%)-containing medium was added. The medium was changed within 24 h and every 2-3 days afterward. For in vivo experiments, 25-to 30-day-old rats were anesthetized with pentobarbital (50 mg͞kg), and left L4 and L5 DRGs were exposed. A viral solution (2 l) containing either rAAV-OR or rAAV-EGFP was slowly (15-20 min) injected into each ganglion with a Hamilton syringe. The wound was then closed; animals were returned to their cages.
Morphological Analysis. Cultured DRG cells were fixed with PBS containing 4% paraformaldehyde and 0.2% picric acid at 4°C for 1 h. To obtain tissue sections, injected rats were perfused with the same fixative. DRGs and the spinal cord were then removed and sectioned (10 m thick) in a cryostat. Morphological integrity of DRGs was examined by staining tissue with hematoxylin͞eosin. To detect exogenous ORs, either the monoclonal mouse anti-His antibody (Qiagen, Valencia, CA, 1:20; for cultured DRGs) or the polyclonal rabbit anti-His antibody (Santa Cruz Biotechnology, 1:200; for tissue sections) was used. Fluorescein anti-mouse or anti-rabbit IgG (Vector Laboratories) was the secondary antibody. A polyclonal anti-OR antibody (DiaSorin, Stillwater, MN, 1:200) was used to label endogenous and exogenous ORs and a rhodamine red-conjugated goat anti-rabbit IgG (Jackson ImmunoResearch) was for visu-alization. The primary anti-OR antibody was specific because the antibody pretreated with the OR peptide immunogen no longer labeled ORs. EGFP was visualized without further treatment. Mouse NeuN (Chemicon, 1:200) was used to label neurons. Mouse anti-N52 (Chemicon, 1:200) was used to label myelinated DRGs; mouse anti-periphrin (Chemicon, 1:200) was used to label cells unmyelinated DRGs. Alexa Fluor 546 goat anti-mouse IgG (Molecular Probes, 1:200) was used for visualization. To avoid the possibility of double-counting, labeled cells in every fifth section were counted.
Western Analyses. Total proteins were extracted from DRGs and the spinal cord of injected rats by using the standard methods (20) . Protein extracts (10-30 g) were subjected to SDS͞PAGE (10% acrylamide). Proteins were transferred onto nitrocellulose membranes and subsequently incubated with rabbit anti-OR antibody (DiaSorin, 1:1,000) for OR detection. Actin, used as an internal control, was labeled with mouse anti-actin antibody (Chemicon, 1:1,000). Blots were detected by using secondary antisera coupled to horseradish peroxidase and developed by using the enhanced chemiluminescence kit (Amersham Biosciences). Blot intensities were analyzed with a LYNX 5000 image analyzer.
Behavioral Tests. Thermal hyperalgesia to radiant heat was assessed as described (21) . Three to four weeks after rAAV injection, rats were acclimated in Plexiglas boxes placed on a platform for 30 min͞day for 5 days. To measure paw withdrawal latencies (PWLs), a radiant heat source was placed under the plantar surface of the hind paw and the time elapsed from the onset of radiant heat stimulation to the withdrawal of the paw was recorded. The heat intensity was adjusted to give a baseline latency of Ϸ10 s; a cutoff time of 30 s was set to prevent possible tissue damage. To obtain baseline PWLs, three measurements separated by a 5-min interval were made for each rat's hind paw and scores were averaged. The antinociceptive effects of morphine were evaluated by measuring PWLs before and every 10 min after the s.c. morphine administration.
To induce inflammation, rats were lightly anesthetized with pentobarbital. Complete Freund's adjuvant (CFA; Mycobacterium butyricum from Difco) emulsion (1:1 peanut oil͞saline, 1 mg of Mycobacterium per ml) was injected into the plantar surface (50 l) of the rat left hind paw 3-4 weeks after infection of rAAV. Behavioral experiments were performed 5-14 days after the CFA injection. -ol]enkephalin (DAMGO) was pressure delivered to the recorded cells through a drug applicator (22) .
Data Analyses. All data were expressed as mean Ϯ SEM. PWLs obtained from different rats were averaged. Changes before and after morphine treatment within one rat group were analyzed with one-way ANOVA followed by post hoc Newman-Keuls analysis. Antinociceptive responses were expressed as maximum possible effect (MPE) by using the relation MPE ϭ (postdrug PWL Ϫ baseline PWL)͞(cutoff PWL Ϫ baseline PWL) ϫ 100. Dose-response curves were plotted as MPE vs. dose and fitted with the logistic equation. The dose estimated to produce 50% MPE, A50, and 95% confidence intervals were determined. The dose-response curves for DAMGO in current measurements were fitted with the Hill equation, i.e., response ϭ (max Ϫ min) ϫ [IC 50 ͞(IC 50 n ϩ dose n )] ϩ min, where max and min are maximal and minimal responses, IC 50 the dose for 50% of the block, and n the Hill coefficient. The 95% confidence band analysis was used to evaluate the significance of the change in the IC 50 and maximal block. To assess the significance of changes between two means, the Student's t test was used. A P Ͻ 0.05 was considered significant.
Results

Stable Enhanced Expression of ORs in DRG Neurons Infected with
rAAV Vectors. Two rAAV vectors were used in this study. One rAAV vector, used in all of the control experiments, was constructed to express the EGFP gene under the control of a NSE promoter. Another rAAV vector was constructed to contain the rat OR cDNA in place of the EGFP gene. A 6ϫHis sequence was fused to the C terminus of the OR gene so that the exogenously introduced ORs could be distinguished from the endogenously expressed ORs with an anti-His antibody. The titer of purified virus, determined by transgene expression in DRG cultures by using a serial dilution of the viral stock, was 4.2 ϫ 10 8 transducing units (t.u.)͞ml for the NSE-EGFP virus (designated as rAAV-EGFP) and 2.6 ϫ 10 8 t.u.͞ml for the NSE-OR virus (rAAV-OR).
We first investigated OR expression in cultured DRG neurons treated with rAAV-OR. The mouse anti-His mAb was used to evaluate the expression of exogenous ORs; the rabbit polyclonal anti-OR antibody was used to probe the expression of all, i.e., both endogenous and exogenous, ORs. In untreated cultured DRG neurons, none of the neurons were His-positive. About 50.0 Ϯ 2.9% (n ϭ 3) of cells expressed ORs endogenously (data not shown). Five to 7 days after adding crude rAAV-OR, 60.0 Ϯ 1.7% (n ϭ 6) of DRG neurons were labeled with anti-His antibody (Fig. 1a Left) and 81.0 Ϯ 3.6% of cells were labeled with anti-OR antibody (Fig. 1a Center). Hislabeled cells were also labeled with anti-OR antibodies (Fig. 1a Right). The OR fluorescence in doubled-labeled neurons was usually much brighter than that in single-labeled neurons. Their cell processes were often labeled intensely. When purified rAAV-OR was used, Ͼ90% of cultured DRG neurons became His-positive (Fig. 1b) .
To infect DRG neurons with rAAV-OR in vivo, a purified viral stock of rAAV-OR was injected into the L4 and L5 ganglia (2 l each). The rats showed no signs of paresis or other abnormalities afterward. The injected DRGs, stained with hematoxylin͞eosin, retained their structural integrity; leukocytes were not present in the ganglia. The immune responses due to rAAV-OR infection were therefore minimal. Studies of three animals in each rat group, 37.3% of neurons in the injected DRGs were brightly labeled with rabbit polyclonal anti-His antibody 3 weeks after the injection. (Fig. 1c Left) . A majority (Ϸ25%) of them were small [diameter (d) Ͻ 25 m] and medium (25 Ͻ d Ͻ 35 m) neurons, which likely mediate nociception. All His-positive neurons were also NeuN-positive (Fig. 1c Center and Right), confirming the neuron specificity of the NSE promoter. The expression remained stable for at least 6 months. No His-labeled cells were found in the DRGs contralateral to the injected side. In injected DRGs, anti-OR antibody labels were found in 76.3% of cells, a percentage significantly higher than the 50.1% of labeled neurons on the contralateral side (Figs. 1 d and  e) . The increase in percentages of neurons expressing ORs suggests that the rAAV-OR viron indeed infects neurons, many of which do not express or minimally express ORs endogenously. We also examined His labels in the spinal cord. His label was seen in axons and presumed nerve terminals in the dorsal column and laminae I-V of the spinal cord ipsi-, but not contralateral, to the injection; no spinal neuron cell bodies were labeled (data not shown).
We further investigated the type of DRG neurons, i.e., nociceptive and nonnociceptive neurons, infected by rAAV. With some exceptions, it is generally believed that large (d Ͼ 35 m) and myelinated neurons mediate nonnociceptive sensations and small (d Ͻ 25 m) and medium (25 Ͻ d Ͻ 35 m) unmyelinated or myelinated neurons mediate nociception (23) . Neuronal types were therefore categorized according to their sizes and myelination. Almost all DRG neurons in the culture were His-labeled (Fig. 1b) , suggesting that rAAV infected both nociceptive and nonnociceptive neurons. However, OR expression in nonnociceptive neurons in vitro was difficult to assess quantitatively because large DRG neurons did not survive as well as small and medium neurons in cultures. The OR expression was therefore quantified in vivo. Because mouse monoclonal His-antibody could not optimally label ORs in vivo, rabbit polyclonal His-antibody had to be used, which prevented us from double-labeling ORs in vivo with anti-His and anti-OR antibodies. Different strategies were used. We first determined the percentages of neurons labeled with the anti-OR antibody in the DRGs ipsi-and contralateral to the rAAV injection (Table 1) . We found that higher percentage of neurons expressing ORs in ipsilateral DRGs. The increase in percentages of neurons expressing ORs (i.e., small cell, 6.8%; medium cells, 9.4%; large cell, 10.0%) suggests that the rAAV-OR viron indeed infects neurons, many of which do not express ORs endogenously. We next double-labeled DRGs with rabbit anti-His antibody and mouse anti-N52, which labels myelinated DRGs (24), or mouse antiperipherin, which labeled unmyelinated DRGs (25) . About 7.3% of small cells, 17.8% of medium cells, and 12.2% of large cells were His-labeled (Table 1) . These percentages were larger than the percentage increases examined with the anti-OR antibody. These results suggest that rAAVs also infect neurons, especially medium-sized, that express ORs endogenously. Furthermore, two-thirds [i.e., (7.3 ϩ 17.8)͞37.3 ϭ 0.67] of exogenous ORs were expressed in small and medium neurons, which likely mediate nociception. A third of exogenous ORs were expressed in large, presumably nonnociceptive, cells.
The rAAV-derived increase in OR expression was further quantified by Western blot analyses. The injected and contralateral ganglia were removed from the animals at different time points and probed with the anti-OR antibody. Compared with the contralateral ganglia, OR expression in the injected DRGs increased with time, plateaued at Ϸ2-fold 14 days after the injection (Fig. 2a) . The delay in reaching the plateau is likely caused by the time for the AAV, which is a single-stranded replication-defective DNA virus, to convert from single-to doubled-stranded DNA (26) . Once it reached a plateau, OR expression remained stable up to 6 months (the longest time point tested; Fig. 2a) . The OR expression in the spinal-cord segments innervated by the L4 and L5 ganglia was increased with a similar time course and reached a maximum increase of 1.5-fold (Fig. 2b) . We also compared OR expression in the DRG and spinal cord before and after inf lammation by using Western analyses (Fig. 2c) . The relative blot intensity, i.e., OR expression, in the DRG and spinal cord of normal saline and rAAV-EGFP rats after inf lammation were not significantly different from their contralateral controls. The OR expression of rAAV-OR rats was considerably higher than the contralateral control (DRG: non-CFA ϭ 1.96 Ϯ 0.02, CFA ϭ 1.94 Ϯ 0.07; spinal cord: non-CFA ϭ 1.48 Ϯ 0.10, CFA ϭ 1.49 Ϯ 0.07). However, inf lammation did not significantly alter OR expression.
Enhanced Antinociceptive Effects of Morphine in rAAV-OR Rats. To determine the functional consequence of the enhanced expression of ORs, we studied the effects of morphine on thermal nociceptive responses, which are mediated by small and medium DRG neurons, in rAAV-injected rats. The left L4-L5 ganglia of rats were injected with either the rAAV-EGFP or rAAV-OR. Three to four weeks later, PWLs to noxious radiant heat were measured from the hind paw ipsilateral to the rAAV injection. The basal PWLs for rats infected with rAAV-OR and rAAV-EGFP were indistinguishable (PWL ϭ 10.08 Ϯ 0.45 s, n ϭ 34 for rAAV-EGFP rats; PWL ϭ 10.29 Ϯ 0.46 s, n ϭ 36 for rAAV- OR rats). In both rat groups, a s.c. morphine injection produced an increase in the PWL, and the antinociceptive effect developed with a similar time course (Fig. 3a) . However, the PWLs in rAAV-OR rats were larger than those measured in rAAV-EGFP rats. To make sure that rAAV-EGFP itself did not produce unforeseeable behavioral consequences, we examined morphine antinociceptive effects on the paw contralateral to the rAAV-OR injection (n ϭ 6) and the paw in rats with saline injected in their DRGs (n ϭ 7). The behavioral responses in these two control groups were similar to the rats treated with rAAV-EGFP (Fig. 3a) . Most control experiments hereafter were done with rAAV-EGFP rats. The enhanced effect of morphine in rAAV-OR rats was observed consistently at different morphine doses. Therefore, the morphine doseresponse, expressed as the MPE, for rAAV-OR rats was shifted to the left of that for rAAV-EGFP rats (Fig. 3b) . The morphine dose to produce 50% MPE, i.e., A50, was 2.34 mg (95% confidence limits, 1.78-2.88 mg) for rAAV-OR rats and was 3.63 mg (2.95-4.27 mg) for rAAV-EGFP. The increased antinociceptive effects of morphine persisted in rAAV-OR rats for at least 3 months (the longest period tested).
We also studied the morphine effects on thermal nociceptive responses in rAAV-EGFP and rAAV-OR rats with inflammation. CFA was injected into the hind paw and nociceptive responses were examined 5-14 days later. Compared with non-CFA-treated rats, the basal PWLs to heat were considerably reduced (PWL ϭ 6.02 Ϯ 0.35 s, n ϭ 12 for rAAV-EGFP rats; PWL ϭ 5.92 Ϯ 0.33 s, n ϭ 19 for rAAV-OR rats). Morphine treatment increased the PWLs in both rAAV-EGFP and rAAV-OR rat groups (Fig. 3c) . The nociceptive effects of morphine in rAAV-OR rats were again larger than those in rAAV-EGFP rats. The extent of increase in PWLs induced by rAAV-OR treatment was more pronounced in CFA rats (Fig. 3c ) than in non-CFA rats (Fig. 3a) . This finding could also be seen in morphine dose-response curves (Fig. 3d) . The increase in the MPEs of rAAV-OR rats, especially for morphine doses Ն4 mg͞kg, was larger after CFA treatment. The A50 for rAAV-OR rats was 2.63-fold lower than that for rAAV-EGFP rats [rAAV-OR, A50 ϭ 3.02 mg (2.75-3.31 mg); rAAV-EGFP, A50 ϭ 7.94 mg (6.6-9.3 mg)]. Thus, enhanced OR expression increases the efficacy of morphine; the increase is further potentiated after inflammation. Comparing the morphine doseresponse curves of non-CFA and CFA-treated rAAV-EGFP rats, the dose-response curve of CFA-treated rAAV-EGFP rats was shifted to the right (non-CFA, A50 ϭ 3.64 mg; CFA, A50 ϭ 7.94 mg) (Fig. 3 b and d) . That is, more opiates are required to overcome the enhanced nociception caused by inflammation. In contrast, the shift in morphine dose-response curve in rAAV-OR rats before and after inflammation (non-CFA, 2.34 mg; CFA, A50 ϭ 3.02 mg) was not statistically significant, a result of the much more pronounced enhancement of antinociceptive effect of morphine in rAAV-OR rats after inflammation.
Enhanced Block of Ca 2؉ Channels in rAAV-OR-Infected Neurons. It is well established that -opioids inhibit high-threshold voltagedependent Ca 2ϩ currents in DRG neurons (27, 28) . To determine whether the enhanced OR expression alters opioid inhibition of Ca 2ϩ currents, we compared the effects of the OR expression after inflammation. CFA was injected in the left paw of rats 3-4 weeks after rAAV infection. Ten days after CFA injection, DRGs and the spinal cord were removed. The OR expression in inflamed rats injected with normal saline (N.S.) or rAAV-EGFP (EGFP) was not significantly different from the contralateral controls. The OR expression in the ipsilateral DRGs or spinal cord of rAAV-OR rats was significantly higher than the contralateral controls. Inflammation did not change the OR expression.
Fig. 3.
Morphine antinociceptive effects are enhanced in rAAV-ORinjected rats. (a) The PWLs after the treatment of 4 mg͞kg morphine in non-CFA (uninflamed) rats. The antinociceptive effects reached a maximum by 30 -40 min and then gradually dissipated in 80 -90 min. The PWLs obtained from the rat paw ipsilateral to the rAAV-EGFP (E; n ϭ 12) or normal saline (‚; n ϭ 6) injection or from the paw contralateral to the rAAV-OR injection (ᮀ; n ϭ 6) were all similar. In contrast, the PWLs obtained from the paw ipsilateral to the rAAV-OR injection (F; n ϭ 10) were larger, suggesting an enhanced antinociceptive effect of morphine. (b) Morphine dose-response curves for non-CFA rats injected with rAAV-EGFP or rAAV-OR. For all morphine doses, the antinociceptive responses of morphine, expressed in MPEs, in rAAV-OR rats were significantly enhanced (n ϭ 5). (c and d) In CFA (inflamed) rats, the antinociceptive effect of morphine in rAAV-OR rats was even more enhanced. The PWLs obtained from rAAV-OR rats (F; n ϭ 5) were much larger than those from rAAV-EGFP rats (E; n ϭ 5; * , P Ͻ 0.05; #, P Ͻ 0.01).
-opioid agonist, DAMGO, on the activity of high-threshold Ca 2ϩ channels in untreated, rAAV-EGFP-treated, and rAAV-OR-treated cultured DRG neurons. rAAV virons were added to neurons 1-2 days after plating. Seven days after the infection, perforated patch whole-cell recordings were performed on the cells. External Ca 2ϩ was replaced by Ba 2ϩ to avoid rapid rundown of current responses. DAMGO was found to block Ba 2ϩ currents in small and medium DRG cells (diameter, 18-35 m). The block was observed for both control (untreated and rAAV-EGFP-treated) and rAAV-OR-treated DRG neurons (Fig. 4) . However, a larger percentage of cells responded to DAMGO inhibition in the rAAV-OR group (89.2%, n ϭ 34) than that in the control groups (untreated cells, 57.1%, n ϭ 14; rAAV-EGFP, 54.5%, n ϭ 11). In addition, the maximal block of Ba 2ϩ currents in rAAV-OR cells was significantly higher (Fig.  4 a and b) . The slowing of activation of the currents in rAAV-OR neurons became more evident. The DAMGO dose required for about half-maximal inhibition in rAAV-OR cells was severalfold lower than that in the control groups (Fig. 4c) . When the dose-response curves of the DAMGO block was fit with the Hill equation, the maximal block was about 22.02 Ϯ 0.01% for untreated cells, 22.02 Ϯ 0.01% for rAAV-EGFP cells, and 31.63 Ϯ 0.03% for rAAV-OR cells. The apparent affinity for DAMGO inhibition (IC 50 ) was 0.53 Ϯ 0.03 M for the rAAV-EGFP and 0.64 Ϯ 0.19 for the untreated cells. The IC 50 was 0.17 Ϯ 0.06 M for the rAAV-OR cells, a 3.1-or 3.8-fold increase in the affinity. Therefore, the potency and efficacy of opioid inhibition are significantly increased after rAAV-OR infection.
Discussion
Introducing transgenes into nociceptive-related neurons presents an exciting therapeutic alternative for the treatment of pain. The technique allows a specific protein to be synthesized and exert its effects in the targeted tissue, thus reducing or even eliminating the problems of short half-life and side effects of classical drugs. Poor gene transfer efficacy, transient transgene expression and toxicity, or immune responses, however, have limited the success of such a genetic approach. Here, we show that these obstacles can be largely circumvented by using rAAV vectors. rAAV under the control of the NSE promoter efficiently drives the expression of ORs exclusively in DRG neurons (Fig.  1) . Toxic effects or immune responses of rAAV infection were not evident. The expression of ORs remained stable during the period when DRG cultures were viable (3-4 weeks) . Furthermore, we demonstrate here an abundant and stable expression of ORs in DRGs and their terminals after rAAV-OR infection. Most exogenous ORs are expressed in small and medium, presumably, nociceptive neurons. We also found that rAAV-OR infects both neurons with minimal endogenous ORs and neurons that express ORs endogenously (Table 1) . Therefore, the enhanced antinociceptive effects of morphine observed in rAAV-OR rats (Fig. 3) could be attributed to more nociceptive neurons that are sensitive to opioids and to enhanced sensitivity to opioids in those neurons that have ORs endogenously. The latter is consistent with the finding that a large number of nociceptors express OR at levels well below its maximal opioid sensitivity (29) . Our observation that exogenous OR expression is limited to DRGs and their terminals agrees with others that gene products caused by rAAV seldom appear at transsynaptic locations (12) . By targeting presynaptic DRG neurons instead of postsynaptic cells, which include both excitatory and inhibitory neurons in the superficial spinal cord, for infection, some unexpected consequences of descending facilitation are avoided (30) . We also found that a substantial number of ORs are expressed in myelinated large DRG cells that do not express endogenous ORs (Table 1) and are presumably nonnociceptive. The behavioral consequences of this change are of great interest and under investigation.
Our behavioral studies show that the increase in ORs does not affect basal nociceptive responses under normal or inflamed conditions, but it significantly enhances the antinociceptive effects of morphine (Fig. 3) . The increased morphine antinociceptive action correlates well with the increased OR expression for at least 3 months (the longest period tested) after infection. Although the mechanisms underlying the increased morphine antinociceptive effect remain to be thoroughly delineated, our studies indicate that the increased antinociceptive responses could arise from the enhanced efficacy and potency of -opioid to inhibit voltage-dependent Ca 2ϩ currents (Fig. 4) . It is well established that a block of Ca 2ϩ channels at the central presynaptic terminals of DRG cells profoundly affects synaptic transmission in the spinal cord (31) (32) (33) . An increase in opioid block of Ca 2ϩ channels in rAAV-OR neurons could give rise to the enhanced opioid inhibition of nociceptive signals in the sensory neurons.
We found that in the control rat groups more opiates are required to overcome the enhanced nociception in the inflammatory state (Fig. 3 b and d) . This result is consistent with the study of Gutstein et al. (34) but is different from other studies that show an enhancement of the antinociceptive effect of morphine after inflammation (35) . The discrepancies among various studies could be attributed to dissimilar inflammatory conditions, different rat species, and varying stress levels induced in animals during behavioral experiments (36) . Some suggest that the enhancing effect of opioids results from inflammationinduced spontaneous up-regulation of ORs in the DRG (37). However, our Western analyses show that inflammation does not change OR expression in the DRG (Fig. 2) , a result consistent with the finding that mRNA levels in the DRG remain unchanged after inflammation (38) . Schafer et al. (38) showed that peripherally applied -opioids produce enhanced analgesic effects in the inflamed paw. They suggested that the enhancement may be produced by an increased axonal transport of ORs in the sciatic nerve and thus an increase in opioid receptors in peripheral nerve terminals (39) . It is of interest to determine whether the level of peripheral opioid receptors in rAAV-OR rats changes in the inflammatory state. One interesting observation is that rAAV-OR infection causes a more pronounced increase in morphine efficacies in the inflammatory state (Fig.  3) . As a result, inflammation no longer induces rightward shift in the morphine dose-response curve. This potentiation of morphine effects in CFA treated rAAV-OR rats clearly is of potential therapeutic interest; the mechanism for the increase needs to be determined. Preferential up-regulation of endogenous opioid peptides after inflammation (35, 40) could be one factor contributing to the increase in morphine efficacy in inflamed rAAV-OR rats.
Our strategy of up-regulating opioid receptor expression in DRGs is different from those of others to deliver opioid genes in the nociceptive system (7) (8) (9) . Because the release of opioids depends on neuronal activity, which is enhanced during nociception, an increase in opioid production would potentiate opioid release, thus reducing basal nociceptive responses after inflammation. On the other hand, chronic nociceptive conditions may induce excessive and prolonged release of opioids thus promoting the development of tolerance. Our approach to up-regulate ORs does not depend on afferent activity. Therefore, basal nociceptive responses are unaffected under either normal or inflamed conditions. The possibility of using low doses of opioids for antinociception at a reduced risk of tolerance development after the rAAV-OR infection (Figs. 3 and 4 ) strongly suggests the therapeutic potential of this approach.
The key advantages of our strategy to up-regulate opioid receptors are: (i) the rAAV viral system induces an efficient and long-lasting (up to 6 months) receptor expression; (ii) the transgene expression can target specifically to DRG neurons, thus avoiding undesired systemic effects of opioids; (iii) the increased OR expression results in a significant enhancement in the antinociceptive effects of morphine; and (iv) the increase in morphine efficacy is further enhanced in the inflammatory state. Furthermore, the stable and specific targeted expression of opioid receptors in rats provides a good model system for determining behavioral consequences and mechanisms underlying this gene transfer approach. A possible disadvantage is that direct injection of rAAV into the DRG could incur tissue damage and thus limits its application in gene therapy. With further refinement in vector design, receptor manipulation, and routes of gene delivery, rAAV opioid receptor infection can be a valid therapeutic strategy for the treatment of acute and chronic pain in humans. Moreover, the same approach can be adapted for other molecules associated with pain processing to provide new ways to alleviate pain resulting from injuries or diseases.
